Full text is available at the source.
Abstract
Phase I study results indicate intratumoral MEDI1191 may enhance antitumor T cell responses.
- MEDI1191 is formulated with lipid nanoparticles to deliver mRNA.
- The treatment is designed to stimulate local production of interleukin-12.
- Intratumoral administration of MEDI1191 is combined with intravenous durvalumab.
- This study represents a first-in-human trial assessing the safety and feasibility of the combination.
Simplified
mRNA Technology